Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization

The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage. Prospects of ending this pandemic rest on the development of effective interventions. Two monoclonal antibody (mAb) therapeutics have received emergency use authorization(1,2), and more are in the pi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Res Sq
Main Authors: Wang, Pengfei, Liu, Lihong, Iketani, Sho, Luo, Yang, Guo, Yicheng, Wang, Maple, Yu, Jian, Zhang, Baoshan, Kwong, Peter D., Graham, Barney S., Mascola, John R., Chang, Jennifer Y., Yin, Michael T., Sobieszczyk, Magdalena, Kyratsous, Christos A., Shapiro, Lawrence, Sheng, Zizhang, Nair, Manoj S., Huang, Yaoxing, Ho, David D.
Formato: Artigo
Idioma:Inglês
Publicado em: American Journal Experts 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7852232/
https://ncbi.nlm.nih.gov/pubmed/33532763
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21203/rs.3.rs-155394/v1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados